PDL BIOPHARMA ANNOUNCES ROCHE DISCONTINUATION OF CO-DEVELOPMENT OF DACLIZUMAB IN ASTHMA

PDL BioPharma, Inc. announced that Roche has discontinued its involvement in the development of daclizumab in asthma, which both companies had been co-developing since 2004. The decision, following a portfolio review at Roche, has no effect on the companies' ongoing collaboration to co-develop daclizumab in transplant maintenance, and the companies intend to proceed with planned Phase 2 studies for the transplant indication during 2007. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/08-30-2006/0004424032&EDATE=)